HOOK | tickerfilter.com

Fundamental analysis

34%

Profitability 25%

Dept financing 10%

Liquidity 66%

Performance 42%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-6.19%

1 Month

-17.07%

3 Months

-55.41%

6 Months

196.09%

1 Year

163.19%

2 Year

142.98%

Key data

Stock price

$1.83

P/E Ratio

-1.04

DAY RANGE

$1.88 - $4.67

EPS

-$5.37

52 WEEK RANGE

$0.52 - $6.62

52 WEEK CHANGE

$131.66

MARKET CAP

50.496 M

YIELD

N/A

SHARES OUTSTANDING

9.655 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

11/07/2024

BETA

0.00

PUBLIC FLOAT

AVERAGE 10 VOLUME

$67,420

AVERAGE 30 VOLUME

$63,892

Company detail

CEO: Jörn Aldag
Region: US
Website: www.hookipapharma.com
Employees: 160
IPO year: -

Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

HOOKIPA Pharma Inc. develops immunotherapeutics targeting infectious diseases and cancers. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers.

HOOK - HOOKIPA Pharma Inc.